arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Forte Biosciences, Inc.

FBRX

$76.80 ▲ +0.19 (+0.25%) at close

12 Visible periods

27 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Forte Biosciences, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap —

Dividend Yield —

Revenue Growth None

Op. Margin None

ROIC -117.6% ↘

FCF / Share None

Trailing P/E —

Price / Book 16.3x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 6, 2026.

12-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$36.00K

↓ -99.8% —

Net Income Profit after all expenses

$-69.38M

↓ -95.5% —

Long-Term Debt Long-term obligations

$26.20M

↑ +622.8% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓

Cash Quality →

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗
Revenue Growth YoY (%)	—	—	—	—	—	—	-99.8% Weak Weak Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-1348%)	43890.2% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+548528%)	—	—	—	—
EPS Growth YoY (%)	61.3% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	51.2% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	-24.6% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	48.4% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—	—	—	—	—
Net Income Growth YoY (%)	-95.5% Weak ↓ Weak Declining Year-over-year change in net income	-12.7% Weak → Weak Stable Year-over-year change in net income	-126.8% Weak ↓ Weak Declining Year-over-year change in net income	36.1% Excellent ↑ Excellent Improving Year-over-year change in net income	53.3% Excellent ↑ Excellent Improving Year-over-year change in net income	26.8% Excellent ↑ Excellent Improving Year-over-year change in net income	-29.7% Weak → Weak Stable Year-over-year change in net income	-25.8% Weak ↑ Weak Improving Year-over-year change in net income	-16.3% Weak Weak Year-over-year change in net income	-45.2% Weak Weak Year-over-year change in net income	—	—

💰 Are margins durable? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗
Operating Margin (%) (%)	—	—	—	—	—	—	—	-254.2% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1795%)	—	—	—	—
Effective Tax Rate (%) (%)	-1.5% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	—	—	—	-0.0% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	-3.6% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	—	—
Profit Margin (%) (%)	—	—	—	—	—	—	—	-271.4% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-2362%)	—	—	—	—
FCF Margin (%) (%)	—	—	—	—	—	—	—	-202.0% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—	—	—	—
FCF / Net Income (x)	0.74x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.87x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.91x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.59x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.77x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.40x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.94x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.74x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.82x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—	—	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗
Return on Invested Capital (%)	-117.6% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-69.7% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-72.7% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-28.3% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-40.9% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-62.0% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-567.0% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-56.3% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-50.4% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	21.9% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	19.6% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-85.4% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-59.5% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-83.3% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-33.1% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-49.6% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-75.6% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-218.4% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-44.5% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-40.9% Weak Weak Operating profit relative to total assets Optimal: > 10%	-89.6% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—
Return on Common Equity (%) (%)	-113.7% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-858%)	-67.6% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-551%)	-89.1% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-694%)	-35.8% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-338%)	-52.2% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-448%)	-78.8% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-625%)	—	-84.2% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-661%)	-54.8% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-465%)	26.9% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+79%)	25.0% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+66%)	—

⚖️ Is the balance sheet risky? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗
Debt to Equity (x)	—	—	—	—	—	—	—	0.45x Good ↑ Good Improving Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-25%)	0.05x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-92%)	-0.08x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-114%)	—	—
Interest Coverage (x)	—	—	—	—	—	—	-16.10x Weak → Weak Stable Operating income divided by interest expense Optimal: > 5x	-15.65x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-19.48x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-15.44x Weak Weak Operating income divided by interest expense Optimal: > 5x	-67.71x Weak Weak Operating income divided by interest expense Optimal: > 5x	—
Net Debt (USD)	$-76.96M	$-22.24M	$-37.12M	$-41.10M	$-42.04M	$-58.77M	$-8.99M	$-14.61M	$-32.31M	$4.73M	$-8.15M	$-4.20M
Debt / EBITDA (x)	—	—	—	—	—	—	—	-0.58x Excellent ↓ Excellent Declining Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-0.10x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-0.33x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	—	—

📊 What does each share earn? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗
Basic EPS, GAAP (USD)	$-4.71	$-12.17	$-24.92	$-20.00	$-38.75	—	—	—	—	—	—	—
Free Cash Flow per Share (USD)	—	—	—	—	$-29.85	—	—	—	—	—	—	—
Book Value per Share (USD)	$4.71	$8.21	$24.30	$46.21	$70.40	$114.92	$11.35	$63.20	$89.38	$-1.41K	—	—
Tangible Book Value per Share (USD)	$4.71	$8.21	$24.30	$46.21	$70.40	$114.92	$11.35	$63.20	$89.38	$-1.41K	—	—
Basic Weighted Avg Shares (shares)	—	—	—	—	558,713	—	—	—	—	—	—	—

🏦 How resilient is the balance sheet? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗
Working Capital (USD)	$59.84M	$52.27M	$34.66M	$38.33M	$40.76M	$57.64M	$9.75M	$81.21M	$73.30M	$18.08M	—	—
LT Debt (USD)	—	—	—	—	—	—	—	$26.20M	$3.62M	$10.24M	—	—
Total Equity (USD)	$60.99M	$52.48M	$35.31M	$38.82M	$41.55M	$58.98M	$10.85M	$58.15M	$71.08M	$-124.42M	$-92.33M	$-70.44M

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗
Sales/Revenue/Turnover (USD)	—	—	—	—	—	—	$36.00K	$18.04M	$41.00K	—	—	—
Depreciation Expense (USD)	$64.00K	$39.00K	$9.00K	—	$36.00K	$54.00K	$843.00K	$625.00K	$292.00K	$255.00K	$232.00K	—
Net Income, GAAP (USD)	$-69.38M	$-35.48M	$-31.48M	$-13.88M	$-21.71M	$-46.49M	$-63.52M	$-48.95M	$-38.93M	$-33.48M	$-23.06M	—
Operating Cash Flow (USD)	$-50.88M	$-30.75M	$-28.71M	$-8.19M	$-16.68M	$-18.42M	$-59.24M	$-34.47M	$-31.13M	—	—	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 12 years · 43 quarters

Forte Biosciences, Inc.

Analytical Summary

12-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare FBRX with peers